Dermavant Sciences’ $200 Million Financing

VISCHER acted as Swiss counsel to Dermavant in the transaction.Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, entered into…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

This content is for Standard 1 Year members only.
Login Join Now